Do you have the information needed to enhance clinical
outcomes and inform treatment planning?
Helping your patients achieve positive clinical outcomes starts with gaining a clear image of the breast to identify potential abnormalities. If an abnormality presents, you want to be able to rule-in or rule-out cancer and to gain the insights needed to inform treatment planning and monitoring. It’s important to have the right mix of technologies available to help attain the information you need to confidently screen, diagnose, stage, plan treatments and monitor your patients.
Here are a few ways the GE Breast Health Advantage can help.
We have an adaptable offering of low and no dose, advanced imaging technologies to deliver superb image quality to help visualize small abnormalities, masses and architectural distortions including: the only FDA-approved automated ultrasound technology for dense breasts, Molecular Breast Imaging, Digital Tomosynthesis, Contrast-Enhanced Spectral Mammography, MR, PET/MR, CT and PET/CT.
For example, the LOGIQ family of hand-held ultrasound products offers consoles that are specifically designed with tools to address the needs of clinicians focused on breast health.
Shear wave elastography enables non–invasive assessment of lesion stiffnessin breast while integrating smoothly with department workflow. The Breast Productivity Package helps provide excellent efficiency and standardization to lesion reporting.
SenoClaireTM Digital Breast Tomosynthesis
SenoClaire is a three-dimensional imaging technology that uses a low-dose short X-ray sweep around the compressed breast with only nine exposures. For average and large breasts (above 45 mm), GE SenoClaire’s 3D view dose is at least 40 percent lower than Hologic Selenia Dimensions.3
Clarient combines innovative diagnostic technologies with world-class pathology expertise to assess and characterize cancer. The Clarient Insight™ Dx Mammostrat™ is a test for estimating the risk for recurrence in hormone-receptor positive, early stage breast cancer that is independent of proliferation and grade.
Comprehensive asset and financial service programs help keep your technology operating at optimal performance levels, provide training and education to your staff, and help avoid technological obsolescence.
1 Newman EA, Guest AB, Helvie MA, et al. (2006) Changes in surgical management resulting from case review at a breast cancer multidisciplinary tumor board. Cancer. 107:2346–2351.
1 Romanoff, et al. (2014, May). Breast Pathology Review: Does It Make a Difference? Annals of Surgical Oncology.
2 National Cancer Institute at the U.S. National Institutes of Health. Breast Cancer Surveillance Consortium. (2014, July 9). Abnormal Interpretations for 2,061,691 Screening Mammography Examinations from 2004 - 2008 -- based on BSBC data through 2009. Retrieved on April 30, 2015 from http://breastscreening.cancer.gov/statistics/benchmarks/screening/2009/table3.html.
3 Comparison data determined on a phantom. N.W. Marshall and H. Bosmans, Medical Physics UZ Leuven. Application of the draft EUREF protocol for Quality
Control of digital breast tomosynthesis (DBT) systems. BHPA 2014.